Русский
JDP2 – a new promising biological marker in cardiovascular pathology
DOI: https://dx.doi.org/10.18565/therapy.2022.5.67-73
Alieva A.M., Reznik E.V., Teplova N.V., Totolyan G.G., Gasanova E.T., Kalova M.R., Sabanchieva E.E., Nikitin I.G.
1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Literature
1. Roth G.A., Mensah G.A., Johnson C.O. et al. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25): 2982–3021. https://dx.doi.org/10.1016/j.jacc.2020.11.010. 2. Shi M., Tang R., Huang F. et al. Cardiovascular disease in patients with type 1 diabetes: Early evaluation, risk factors and possible relation with cardiac autoimmunity. Diabetes Metab Res Rev. 2021; 37(6): e3423. https://dx.doi.org/10.1002/dmrr.3423. 3. Алиева А.М., Резник Е.В., Гасанова Э.Т. с соавт. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018; 5: 333–345. [Alieva A.M., Reznik E.V., Hasanova E.T. et al. Clinical value of blood biomarkers in patients with chronic heart failure. Arkhiv vnutrenney meditsiny = Archives of Internal Medicine. 2018; 5: 333–345 (In Russ.)]. https://dx.doi.org/10.20514/2226-6704-2018-8-5-333-345. EDN: YKJWIP. 4. Алиева А.М., Пинчук Т.В., Алмазова И.И. и с соавт. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021; 6: 522–526. [Alieva A.M., Pinchuk T.V., Almazova I.I. et al. Dinical value of blood biomarker ST2 in patients with chronic heart failure. Consilium Medicum. 2021; 6: 522–526 (In Russ.)].https://dx.doi.org/10.26442/20751753.2021.6.200606. EDN: ZWUXUD. 5. Euler G., Kockskamper J., Schulz R., Parahuleva M.S. JDP2, a novel molecular key in heart failure and atrial fibrillation? Int J Mol Sci. 2021; 22(8): 4110. https://dx.doi.org/10.3390/ijms22084110. 6. Tsai M.H., Wuputra K., Lin Y.C. et al. Multiple functions of the histone chaperone Jun dimerization protein 2. Gene. 2016; 590(2): 193–200. https://dx.doi.org/10.1016/j.gene.2016.03.048. 7. Aronheim A., Zandi E., Hennemann H. et al. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol. 1997; 17(6): 3094–102. https://dx.doi.org/10.1128/MCB.17.6.3094. 8. Darlyuk-Saadon I., Weidenfeld-Baranboim K., Yokoyama K.K. et al. The bZIP repressor proteins, c-Jun dimerization protein 2 and activating transcription factor 3, recruit multiple HDAC members to the ATF3 promoter. Biochim Biophys Acta. 2012; 1819(11–12): 1142–53. https://dx.doi.org/10.1016/j.bbagrm.2012.09.005. 9. Tanigawa S., Lee C.H., Lin C.S. et al. Jun dimerization protein 2 is a critical component of the Nrf2/MafK complex regulating the response to ROS homeostasis. Cell Death Dis. 2013; 4(11): e921. https://dx.doi.org/10.1038/cddis.2013.448. 10. Maruyama K., Fukasaka M., Vandenbon A. et al. The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation. Immunity. 2012; 37(6): 1024–36. https://dx.doi.org/10.1016/j.immuni.2012.08.022. 11. Nakade K., Pan J., Yoshiki A. et al. JDP2 suppresses adipocyte differentiation by regulating histone acetylation. Cell Death Differ. 2007; 14(8): 1398–405. https://dx.doi.org/10.1038/sj.cdd.4402129. 12. Mimura J., Inose-Maruyama A., Taniuchi S. et al. Concomitant Nrf2- and ATF4-activation by carnosic acid cooperatively induces expression of cytoprotective genes. Int J Mol Sci. 2019; 20(7): 1706. https://dx.doi.org/10.3390/ijms20071706. 13. Wang S., Chen X.A., Hu J. et al. ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3-56 in triple-negative breast cancer cells. Mol Cancer Ther. 2015; 14(4): 877–88. https://dx.doi.org/10.1158/1535-7163.MCT-14-1093-T. 14. Liu Y., He J., Chen R. et al. AP-1 activity is a major barrier of human somatic cell reprogramming. Cell Mol Life Sci. 2021; 78(15): 5847–63. https://dx.doi.org/10.1007/s00018-021-03883-x. 15. Maciejak A., Kiliszek M., Michalak M. et al. Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure. Genome Med. 2015; 7(1): 26. https://dx.doi.org/10.1186/s13073-015-0149-z. 16. Qiu L., Liu X. Identification of key genes involved in myocardial infarction. Eur J Med Res. 2019; 24(1): 22.https://dx.doi.org/10.1186/s40001-019-0381-x. 17. Kehat I., Heinrich R., Ben-Izhak O. et al. Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. Cardiovasc Res. 2006; 70(3): 543–54. https://dx.doi.org/10.1016/j.cardiores.2006.02.018. 18. Wang S., Cao N. Uncovering potential differentially expressed miRNAs and targeted mRNAs in myocardial infarction based on integrating analysis. Mol Med Rep. 2020; 22(5): 4383–95. https://dx.doi.org/10.3892/mmr.2020.11517. 19. Heger J., Bornbaum J., Wurfel A. et al. JDP2 overexpression provokes cardiac dysfunction in mice. Sci Rep. 2018; 8(1): 7647.https://dx.doi.org/10.1038/s41598-018-26052-w. 20. Hill C., Wurfel A., Heger J. et al. Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. Cardiovasc Res. 2013; 99(1): 121–28. https://dx.doi.org/10.1093/cvr/cvt094. 21. Koren L., Alishekevitz D., Elhanani O. et al. ATF3-dependent cross-talk between cardiomyocytes and macrophages promotes cardiac maladaptive remodelling. Int J Cardiol. 2015; 198: 232–40. https://dx.doi.org/10.1016/j.ijcard.2015.06.099. 22. Kalfon R., Friedman T., Eliachar S. et al. JDP2 and ATF3 deficiencies dampen maladaptive cardiac remodeling and preserve cardiac function. PLoS One. 2019; 14(2): e0213081. https://dx.doi.org/10.1371/journal.pone.0213081. 23. Parahuleva M.S., Kockskamper J., Heger J. et al. Structural, pro-inflammatory and calcium handling remodeling underlies spontaneous onset of paroxysmal atrial fibrillation in JDP2-overexpressing mice. Int J Mol Sci. 2020; 21(23): 9095.https://dx.doi.org/10.3390/ijms21239095. 24. Kehat I., Hasin T., Aronheim A. The role of basic leucine zipper protein-mediated transcription in physiological and pathological myocardial hypertrophy. Ann N Y Acad Sci. 2006; 1080: 97–109. https://dx.doi.org/10.1196/annals.1380.009. 25. Huang S., Tao W., Guo Z. et al. Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p. Gene. 2019; 701: 1–8. https://dx.doi.org/10.1016/j.gene.2019.02.098. 26. Алиева А.М., Батов М.А., Воронкова К.В. с соавт. Реналаза – новый инструмент в многокомпонентной оценке сердечной недостаточности. Клиницист. 2021; 1–4: 42–46. [Alieva A.M., Batov M.A., Voronkova K.V. et al. Renalase – a new instrument in multicomponent heart failure assessment. Klinitsist = Clinician. 2021; 1–4: 42–46 (In Russ.)].https://dx.doi.org/10.17650/1818-8338-2021-15-1-4-K644. EDN: HJAJMY. 27. Алиева А.М., Пинчук Т.В., Воронкова К.В. и др. Неоптерин – биомаркер хронической сердечной недостаточности (обзор современной литературы). Consilium Medicum. 2021; 10: 756–759. [Alieva A.M., Pinchuk T.V., Voronkova K.V. et al. Neopterin is a biomarker of chronic heart failure (review of modern literature). Consilium Medicum. 2021; 10: 756–759 (In Russ.)].https://dx.doi.org/10.26442/20751753.2021.10.201113. EDN: SKCMCT. 28. Алиева А.М., Байкова И.Е., Кисляков В.А. с соавт. Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью. Терапевтический архив. 2019; 9: 145–149. [Aliyeva A.M., Baykova I.E., Kislyakov V.A. et al. Galactin-3: diagnostic and prognostic value in patients with chronic heart failure. Terapevticheskiy arkhiv = Therapeutic Archive. 2019; 9: 145–149 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2019.09.000226. EDN: NSZGZS. 29. Алиева А.М., Алмазова И.И., Пинчук Т.В. с соавт. Значение копептина в диагностике и прогнозе течения сердечно-сосудистых заболеваний. Клиническая медицина. 2020; 3: 203–209. [Alieva A.M., Almazova I.I., Pinchuk T.V. et al. The value of copeptin in the diagnosis and prognosis of cardiovascular diseases. Klinicheskaya meditsina = Clinical Medicine. 2020; 3: 203–209 (In Russ.)].https://dx.doi.org/10.30629/0023-2149-2020-98-3-203-209. EDN: IBOPWG. 30. Алиева А.М., Алмазова И.И., Пинчук Т.В. с соавт. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020; 5: 83–86. [Alieva A.M., Almazova I.I., Pinchuk T.V. et al. Fractalkin and cardiovascular disease. Consilium Medicum. 2020; 5: 83–86 (In Russ.)]. https://dx.doi.org/10.26442/20751753.2020.5.200186. EDN: IGGQHI.
About the Autors
Amina Magomedovna Alieva, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: amisha_alieva@mail.ru.
ORCID: https://orcid.org/0000-0001-5416-8579. SPIN-code: 2749-6427
Elena V. Reznik, Dr. med. habil, professor, head of the Department of propaedeutics of internal diseases of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, general practitioner, cardiologist, doctor of functional diagnostics, ultrasound diagnostics at City Clinical Hospital No. 31 of the Healthcare Department of Moscow. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: elenaresnik@gmail.com. ORCID: https://orcid.org/0000-0001-7479-418X. SPIN-code: 3494-9080. Researcher ID: N-6856-2016
Natalia V. Teplova, Dr. med. habil, professor, head of the Department of clinical pharmacology of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. ORCID: https://orcid.org/0000-0002-7181-4680
Gayane G. Totolyan, PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: tgg03@mail.ru
Elvina T. Gasanova, postgraduate student of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str.
Marina R. Kalova, postgraduate student of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: marina717717@mail.ru. ORCID: https://orcid.org/0000-0002-8949-4523
Elina E. Sabanchieva, 6th year student of the Faculty of general medicine, A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str
Igor G. Nikitin, Dr. med. habil, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: igor.nikitin.64@mail.ru. ORCID: https://orcid.org/0000-0003-1699-0881
Similar Articles
